TIDMOXB
RNS Number : 1127A
Oxford Biomedica PLC
28 May 2021
Oxford Biomedica
Result of Annual General Meeting
Oxford, UK - 28 May 2021: Oxford Biomedica plc (LSE:OXB), a
leading gene and cell therapy group, announces today that all
resolutions proposed were duly passed at its Annual General Meeting
(AGM), held at 3pm on 27 May 2021 in Oxford. As proposed in the
Notice of AGM, all resolutions were decided by poll vot e.
The full text of all the resolutions can be viewed in the Notice
of Meeting by visiting the Group's website at www.oxb.com
Copies of the document setting out the above resolutions passed
at the 2021 AGM have been submitted to the National Storage
Mechanism and will shortly be available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
On the Record Date (25 May 2021) there were 82,543,197 ordinary
shares of 50 pence each in issue, each carrying one vote per
share.
Votes
Votes at
at other Total
Resolution Votes Chairman's proxy Votes Votes votes
For Discretion Discretion Against Withheld* cast Result
Ordinary resolutions
-------------------------------------------------- ------------ ----------- ------------ ----------- -------
To receive
the Company's
Accounts,
the Reports
of the Directors
and Auditor
and the
Strategic
Report for
the year
ended 31
December 58,334,279 8,574 1,440
1 2020 (99.99%) (0.01%) 0 (0.00%) 59,353 58,344,293 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To receive
the Directors'
Remuneration
Report and
the Report
of the Auditor
on the Remuneration
Report for
the year
ended 31
December 57,033,865 8,574 731,131
2 2020 (98.72%) (0.01%) 0 (1.27%) 630,076 57,773,570 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To approve
the Directors'
Remuneration 46,429,406 8,574 10,926,461
3 Policy (80.94%) (0.01%) 0 (19.05%) 1,039,205 57,364,441 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To appoint
Dr. Roch
Doliveux 57,832,864 8,574 554,706
4 as a Director. (99.04%) (0.01%) 0 (0.95%) 7,502 58,396,144 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To appoint
Professor
Dame Kay
Davies as 58,385,668 8,574 1,640
5 a Director (99.99) (0.01%) 0 (0.00%) 7,764 58,395,882 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To appoint
Dr. Siyamak
Rasty as 58,325,223 8,574 62,347
6 a Director (99.88%) (0.01%) 0 (0.11%) 7,502 58,396,144 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To reappoint
John Dawson 58,194,899 8,574 192,871
7 as a Director (99.66%) (0.01%) 0 (0.33%) 7,302 58,396,344 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To reappoint
Stuart Paynter 58,195,041 8,574 192,729
8 as a Director (99.66%) (0.01%) 0 (0.33%) 7,302 58,396,344 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To reappoint
Stuart Henderson 55,957,927 8,574 2,423,167
9 as a Director (95.84%) (0.01%) 0 (4.15%) 13,978 58,389,668 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To reappoint
Dr. Heather
Preston 55,966,994 8,574 2,421,352
10 as a Director (95.84%) (0.01%) 0 (4.15%) 6,726 58,396,920 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To reappoint
Robert Ghenchev 58,193,434 8,574 194,336
11 as a Director (99.66%) (0.01%) 0 (0.33%) 7,302 58,396,344 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To reappoint
KMPG LLP 58,376,747 8,674 6,633
12 as auditor (99.98%) (0.01%) 0 (0.01%) 11,592 58,392,054 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To authorise
the Directors
to agree
the remuneration 57,756,307 8,574 5,556
13 of the auditor (99.98%) (0.01%) 0 (0.01%) 633,209 57,770,437 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To amend
the rules
of the Oxford
Biomedica
2015
Long Term
Incentive 46,776,691 8,574 10,579,473
14 Plan (81.55%) (0.01%) 0 (18.44%) 1,038,908 57,364,738 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To amend
the rules
of the Oxford
Biomedica
2015
Executive
Share Option 46,773,232 8,574 10,582,625 10,582,625
15 Scheme (81.54%) (0.01%) 0 (18.45%) (18.45%) 57,364,431 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To authorise
the Directors
to allot 55,826,926 8,574 1,936,496
16 shares (96.64%) (0.01%) 0 (3.35%) 631,650 57,771,996 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
Special resolutions
-------------------------------------------------- ------------ ----------- ------------ ----------- -------
To authorise
the Directors
to disapplypre-emption 57,477,832 8,574 286,354
17 rights (99.49%) (0.01%) 0 (0.50%) 630,886 57,772,760 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To authorise
the Directors
to further
disapply
pre-emption
rights foracquisitions
and specified
capital 57,477,350 8,574 286,636
18 investments (99.49%) (0.01%) 0 (0.50%) 631,086 57,772,560 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
To permit
the Directors
to convene
general
meetings
(other than
annual general
meetings)
on not less
than 14 56,393,012 8,574 1,996,782
19 days' notice (96.57%) (0.01%) 0 (3.42%) 5,278 58,398,368 Passed
----------------------- ----------- ------------ ------------ ----------- ------------ ----------- -------
* A vote withheld is not a vote in law and is not counted
towards votes cast in respect of a resolution.
-Ends-
Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Catherine Isted, Head of Corporate T: +44 (0)1865 783 000
Development & IR T: +44 (0)1865 783 000
T: +44 (0)1865 954 161 / E: ir@oxb.com
Consilium Strategic Communications T: +44 (0)20 3709 5700
Mary-Jane Elliott/Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R)), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb, Sio
Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics,
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy
Consortium and Imperial Innovations, through which it has long-term
economic interests in other potential gene and cell therapy
products. Additionally the group has signed a three year master
supply and development agreement with AstraZeneca for large-scale
manufacturing of the adenoviral based COVID-19 vaccine candidate,
AZD1222. Oxford Biomedica is based across several locations in
Oxfordshire, UK and employs more than 670 people. Further
information is available at www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGSEDESWEFSELI
(END) Dow Jones Newswires
May 28, 2021 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Sep 2023 to Sep 2024
